PreMD Inc. Announces Debenture Financing

    TORONTO, March 3 /CNW/ - Predictive medicine company PreMD Inc. (TSX:
PMD; Amex:   PME) ("PreMD" or the "Company") today announced that it has
completed an agreement with Midsummer Investment, Ltd. with respect to an
offering of unsecured debentures (the "Debentures"). Several additional
existing institutional, qualified investors and insiders have also agreed to
participate. Under the terms of the agreement, PreMD will issue up to CDN
$1.22 million of the Debentures.
    The Debentures mature 18 months after the date of issuance at an amount
equal to CDN$1,176 per CDN$1,000 principal amount. The Company has agreed to
certain pre-payable forced redemptions at the option of the holders or the
Company. The proceeds from the private placement are to be used for general
corporate purposes.
    The Company will also issue approximately five million common share
purchase warrants (the "Warrants"), each Warrant being exercisable for a
period of five years into one common share at $0.2759, a price equal to 100%
of the 5-day volume-weighted average price of the common shares on the Toronto
Stock Exchange.
    The sale of the Debentures and Warrants is expected to close on or before
March 12, 2008 subject to the satisfaction of certain closing conditions and
any necessary regulatory approvals from the American Stock Exchange and the
Toronto Stock Exchange.
    The common shares issuable upon exercise of the Warrants will be subject
to a Canadian statutory hold period of four months and a day after the closing
date. In addition, neither the Debentures nor the Warrants have been
registered with the United States Securities and Exchange Commission (the
"SEC") or the securities commission of any state in reliance upon one or more
exemptions from the securities registration requirements pursuant to the
Securities Act of 1933, as amended (the "US Securities Act"), and,
accordingly, may not be offered or sold except pursuant to an effective
registration statement under the US Securities Act or pursuant to an available
exemption from, or in a transaction not subject to, the registration
requirements of the US Securities Act and in accordance with applicable state
securities laws. PreMD has agreed to prepare and use its commercially
reasonable best efforts to file a registration statement (the "Registration
Statement") with the SEC on or before the date which is 180 days after the
closing date of the transaction. Further, PreMD has also agreed to use its
commercially reasonable best efforts to cause the Registration Statement to be
declared effective under the US Securities Act as promptly as possible after
the filing of the Registration Statement, and shall use its commercially
reasonable best efforts to keep the Registration Statement continuously
effective under the US Securities Act until all Registrable Securities have
been sold or may be sold without volume restrictions pursuant to Rule 144(k).

    About PreMD Inc.

    PreMD Inc. is a leader in predictive medicine, dedicated to developing
rapid, non-invasive tests for the early detection of life-threatening
diseases. PreMD's cardiovascular products include a line of non-invasive skin
cholesterol tests. PreMD's other skin cholesterol products include PREVU(*) LT,
a skin cholesterol test designed for use in the life insurance industry. The
Company's cancer tests include ColorectAlert(TM), LungAlert(TM) and a breast
cancer test. PreMD's head office is located in Toronto, Ontario and its
research and product development facility is at McMaster University in
Hamilton, Ontario. For more information about PreMD, please visit

    This press release contains forward-looking statements. These statements
involve known and unknown risks and uncertainties, which could cause the
Company's actual results to differ materially from those in the
forward-looking statements. Such risks and uncertainties include, among
others, the successful development or marketing of the Company's products, the
competitiveness of the Company's products if successfully commercialized, the
lack of operating profit and availability of funds and resources to pursue R&D
projects, the successful and timely completion of clinical studies, product
liability, reliance on third-party manufacturers, the ability of the Company
to take advantage of business opportunities, uncertainties related to the
regulatory process, and general changes in economic conditions. In addition,
while the Company routinely obtains patents for its products and technology,
the protection offered by the Company's patents and patent applications may be
challenged, invalidated or circumvented by our competitors and there can be no
guarantee of our ability to obtain or maintain patent protection for our
products or product candidates.
    Investors should consult the Company's quarterly and annual filings with
the Canadian and U.S. securities commissions for additional information on
risks and uncertainties relating to the forward-looking statements. Investors
are cautioned not to rely on these forward-looking statements. PreMD is
providing this information as of the date of this press release and does not
undertake any obligation to update any forward-looking statements contained in
this press release as a result of new information, future events or otherwise.

    (*) Trademark

    %SEDAR: 00007927E          %CIK: 0001179083

For further information:

For further information: Ron Hosking, Vice-President Finance and CFO,
Tel: (416) 222-3449 ext. 24, Email:; Michelle Rabba,
Manager, Corporate Communications, Tel: (416) 222-3449 ext 25, Email:

Organization Profile


More on this organization

Custom Packages

Browse our custom packages or build your own to meet your unique communications needs.

Start today.

CNW Membership

Fill out a CNW membership form or contact us at 1 (877) 269-7890

Learn about CNW services

Request more information about CNW products and services or call us at 1 (877) 269-7890